The UC Davis Cancer Center, the only NCI-designated cancer center in the Central Valley of California, is the advanced cancer care provider for a population of five million, the only significance point of access to early phase cancer clinical trials in its Northern California region, and together with its collaborator, the Lawrence Livermore National Laboratory [LLNL], the region's principal cancer research organization. Since its founding thirteen years ago, the UC Davis Cancer Center has provided increasingly progressive leadership to, organization of, and support for cancer investigation. In the first sections, we recapitulate briefly the milestones leading up to NCI designation (July 1, 2002). In subsequent sections, we focus on decisions, achievements, and directions characterizing the center's first two years of its Cancer Center Support Grant [CCSG]. In concluding sections, we focus on program and organizational accomplishments, future direction, and geography.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA093373-04S2
Application #
7122157
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
2005-07-01
Project End
2006-06-30
Budget Start
2005-07-01
Budget End
2006-06-30
Support Year
4
Fiscal Year
2005
Total Cost
$246,999
Indirect Cost
Name
University of California Davis
Department
Urology
Type
Schools of Medicine
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Riess, Jonathan W; Gandara, David R; Frampton, Garrett M et al. (2018) Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. J Thorac Oncol 13:1560-1568
Withers, Sita S; Moore, Peter F; Chang, Hong et al. (2018) Multi-color flow cytometry for evaluating age-related changes in memory lymphocyte subsets in dogs. Dev Comp Immunol 87:64-74
Zhang, Jin; Xu, Enshun; Ren, Cong et al. (2018) Genetic Ablation of Rbm38 Promotes Lymphomagenesis in the Context of Mutant p53 by Downregulating PTEN. Cancer Res 78:1511-1521
Rowson-Hodel, A R; Wald, J H; Hatakeyama, J et al. (2018) Membrane Mucin Muc4 promotes blood cell association with tumor cells and mediates efficient metastasis in a mouse model of breast cancer. Oncogene 37:197-207
Wang, Minan; Yao, Li-Chin; Cheng, Mingshan et al. (2018) Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy. FASEB J 32:1537-1549
York, D; Sproul, C D; Chikere, N et al. (2018) Expression and targeting of transcription factor ATF5 in dog gliomas. Vet Comp Oncol 16:102-107
Fletcher, Kyle; Klosterman, Steven J; Derevnina, Lida et al. (2018) Comparative genomics of downy mildews reveals potential adaptations to biotrophy. BMC Genomics 19:851
Wang, Fuli; Zhang, Hongyong; Ma, Ai-Hong et al. (2018) COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin. Mol Cancer Ther 17:474-483
Yuan, Ye; He, Yixuan; Bo, Ruonan et al. (2018) A facile approach to fabricate self-assembled magnetic nanotheranostics for drug delivery and imaging. Nanoscale 10:21634-21639
Seo, Jai Woong; Tavaré, Richard; Mahakian, Lisa M et al. (2018) CD8+ T-Cell Density Imaging with 64Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols. Clin Cancer Res 24:4976-4987

Showing the most recent 10 out of 836 publications